We are live on ! Find out more
ATXI

Avenue Therapeutics, Inc. Common Stock
ATXI

Delisted

ATXI was delisted on the 18th of March, 2025.

Back to rankings

24 hedge funds and large institutions have $2.88M invested in Avenue Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 2 increasing their positions, 10 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% less funds holding

Funds holding: 30 → 24 (-6)

38% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 16

74% less capital invested

Capital invested by funds: $11.1M → $2.88M (-$8.23M)

80% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 10

Holders
24
Holders Change
-6
Holders Change %
-20%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
2
Reduced
10
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$345K
2
Millennium Management
Millennium Management
New York
+$321K
3
ASN
Advisory Services Network
Georgia
+$153K
4
E
Ergoteles
New York
+$133K
5
VF
Virtu Financial
New York
+$114K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$1.38M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$1.09M
3
State Street
State Street
Massachusetts
-$873K
4
Northern Trust
Northern Trust
Illinois
-$276K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$232K
Name Holding Trade Value Shares
Change 		Change in
Stake
State Street
26
State Street
Massachusetts
– -$873K -128 Closed
N
27
Nuveen
North Carolina
– -$186K -27 Closed
Invesco
28
Invesco
Georgia
– -$99K -14 Closed
Bank of New York Mellon
29
Bank of New York Mellon
New York
– -$91K -13 Closed
Charles Schwab
30
Charles Schwab
California
– -$87K -13 Closed
TI
31
Trexquant Investment
Connecticut
– -$84K -12 Closed
Squarepoint
32
Squarepoint
New York
– -$71K -10 Closed
California State Teachers Retirement System (CalSTRS)
33
California State Teachers Retirement System (CalSTRS)
California
– -$61K -9 Closed
New York State Common Retirement Fund
34
New York State Common Retirement Fund
New York
– -$29.6K -6 Closed
Deutsche Bank
35
Deutsche Bank
Germany
– -$26K -4 Closed
AIG
36
American International Group
New York
– -$24 -3 Closed
Wells Fargo
37
Wells Fargo
California
– -$14.8K -3 Closed
AIP
38
Ameritas Investment Partners
Nebraska
– -$4K -1 Closed
BCA
39
Berman Capital Advisors
Georgia
– -$3K -1 Closed
Legal & General Group
40
Legal & General Group
United Kingdom
– -$5K -1 Closed
Bank of Montreal
41
Bank of Montreal
Ontario, Canada
– -$1K – –
Citigroup
42
Citigroup
New York
– -$3K – –
1
2

ATXI Hedge Fund Activity: Q2 2021 in Review

24 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q2 2021, worth a combined $2.88M — down 74% from $11.1M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of ATXI and 10 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $345K. The largest seller was BlackRock, cutting an estimated $1.38M.

  • 24 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q2 2021, down from 30 in Q1 2021.
  • Funds reported $2.88M of Avenue Therapeutics, Inc. Common Stock stock for Q2 2021, down 74% quarter-over-quarter.
  • 10 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q2 2021 and 16 closed out, a net change of -6 holders.
  • The largest Avenue Therapeutics, Inc. Common Stock buyer in Q2 2021 was Renaissance Technologies, an estimated $345K added.
  • The largest Avenue Therapeutics, Inc. Common Stock seller in Q2 2021 was BlackRock, an estimated $1.38M sold.

Based on aggregated 13F filings for Q2 2021.